NuVasive shares' mean target price set at $54

Spinal Tech

Analysts covering NuVasive stock have set a mean target price of $54.5 for its shares, according to a Stock Watchman report.

The price target is the mean estimate from the 10 research brokerages that recently issued reports on the firm. On a scale of one to five, with one representing a strong buy and five representing a strong sell, the equity is ranked 1.67 based on broker recommendations. In the long term, analysts have estimated a consensus mean earnings per share of $1.09 for the current year, according to the report.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers